| |
|
|
|
|
Median duration of chemotherapy |
Median Outcome (months) |
Fist three most common reasons of discontinuation (%of patients) |
| First Author |
Year |
No. of patients |
Line of
treatment |
Arms |
No. of
cycles |
Months |
PFS |
OS |
| Rothenberg |
2008 |
627 |
2° |
Folfox |
8,5 |
NR |
4,8 |
12,5 |
PD (46.0) |
AE (14.0) |
NR |
| |
|
|
|
Xelox |
6 |
NR |
4,7 |
11,9 |
PD (38.0) |
AE (21.0) |
NR |
| Cassidy |
2008 |
2034 |
1° |
Folfox (or Folfox/Placebo) |
10 |
NR |
7,7 |
Pooled folfox
arms: 19,6 |
NR |
NR |
AE (25.0) |
| |
|
|
|
Folfox/Bev |
12 |
NR |
9,4 |
NR |
NR |
AE (30.0) |
| |
|
|
|
Xelox (or Xelox/ Placebo) |
7 |
NR |
7,3 |
Pooled xelox
arms: 19,8 |
NR |
NR |
AE (26.0) |
| |
|
|
|
Xelox/Bev |
8 |
NR |
9,3 |
NR |
NR |
AE (31.0) |
| |
|
|
|
|
|
|
|
|
|
|
|
| Saltz |
2008 |
1401 |
1° |
Folfox/Bev |
NR |
6,3 |
8,0 |
19,9 |
PD (29.0) |
AE (30.0) |
PR (9.0) |
| |
|
|
|
Xelox/Bev |
| |
|
|
|
Folfox/Placebo |
NR |
5,8 |
9,4 |
21,3 |
PD (47.0) |
AE (21.0) |
PR (8.0) |
| |
|
|
|
Xelox/Placebo |
| Sobrero |
2008 |
1298 |
2° |
Cet/iri |
NR |
3,5 |
4,0 |
10,7 |
PD (67.5) |
PR (7.7) |
AE (6.5) |
| |
|
|
|
Iri |
NR |
2,4 |
2,6 |
10,0 |
PD (68.0) |
PR (6.6) |
AE (4.8) |
| Haller |
2008 |
628 |
2° |
Irox |
6 |
NR |
5,3 |
13,4 |
PD (54.0) |
PR (16.0) |
AE (13.0) |
| |
|
|
|
Iri |
4 |
NR |
2,8 |
11,1 |
PD (66.0) |
AE (13.0) |
PR (10.0) |
| Cunningham |
2009 |
725 |
1° |
Oxa/FU CIV Arm A |
10 (information on total patients) |
NR |
A: 7,9 |
A: 15,9 |
PD (43.0) |
AE (17.1) |
PR (13.5) |
| |
|
|
|
Folfox4 Arm A |
NR |
|
|
|
|
|
| |
|
|
|
FU CIV Arm B |
NR |
B: 5,9 |
B: 15,2 |
PD (61.4) |
PR (11.5) |
AE (4.7) |
| |
|
|
|
LV5FU2 Arm B |
NR |
|
|
|
|
|
| Van Cutsem |
2009 |
1217 |
1° |
Folfiri |
NR |
6 |
8,0 |
18,8 |
NR |
| |
|
|
|
Folfiri/Cet |
NR |
6 |
8,9 |
19,9 |
| Tol |
2009 |
755 |
1° |
Xelox/Bev |
10 |
7 |
10,7 |
20,3 |
PD (54.0) |
AE (25.9) |
PR (6.1) |
| |
|
|
|
Xelox/Cet |
9 |
6 |
9,4 |
19,4 |
PD (48.5) |
AE (29.6) |
PR (7.5) |
| Hecht |
2009 |
1053 |
1° |
Folfox/PanBev |
NR |
NR |
9,8 |
20,7 |
PD (29.0) |
AE (22.0) |
PR (16.0) |
| |
|
|
|
Folfox/Bev |
NR |
NR |
11,5 |
24,5 |
PD (26.0) |
AE (24.0) |
PR (21.0) |
| |
|
|
|
Folfiri/PanBev |
NR |
NR |
10,0 |
Not Estimable |
PD (35.0) |
AE (17.0) |
PR (15.0) |
| |
|
|
|
Folfiri/Bev |
NR |
NR |
12,5 |
19,8 |
PD (27.0) |
PR (26.0) |
AE (6.0) |
| Douillard |
2010 |
1183 |
1° |
Folfox/Pan |
FU 12;
Oxa 11;
Pan 10 |
NR |
9,6 |
23,9 |
PD, AE, PR
% or absolute number were not specified |
| |
|
|
|
Folfox |
FU 12;
Oxa 11 |
NR |
8,0 |
19,7 |
| Peeters |
2010 |
1186 |
2° |
Folfiri/Pan |
NR |
NR |
5,9 |
14,5 |
PD, AE, PR
% or absolute number were not specified |
| |
|
|
|
Folfiri |
NR |
NR |
3,9 |
12,5 |
| Maughan |
2011 |
2445 |
1° |
Folfox or Xelox |
NR |
7,2 |
8,6 |
17,9 |
NR |
| |
|
|
|
Folfox/Cet or Xelox/Cet |
NR |
7,2 |
8,6 |
17,0 |
| Hecht |
2011 |
1168 |
1° |
Folfox/Vatalanib |
NR |
6,4 |
7,7 |
21,4 |
PD (51.2) |
AE (22.3) |
PR (14.7) |
| |
|
|
|
Folfox/Placebo |
NR |
7,8 |
7,6 |
20,5 |
PD (66.5) |
AE (12.1) |
PR (10.1) |
| Schmoll |
2012 |
1805 |
1° |
Folfox/Ced |
10 |
NR |
9,9 |
22,8 |
PD (43.2) |
PR (20.7) |
AE (19.2) |
| |
|
|
|
Folfox/Bev |
12 |
NR |
10,3 |
21,4 |
PD (42.7) |
PR (18.6) |
AE (18.4) |
| Madi |
2012 |
2445 |
1° |
Xelox vs Folfox |
NR |
NR |
7,4 vs 8,8 |
15,4 vs 14,9 |
NR |
| |
|
|
|
Xelox/CetvsFolfox/Cet |
NR |
NR |
7,4 vs 8,5 |
15,0 vs 14,9 |
| Van Cutsem |
2012 |
1401 |
2° |
Folfiri/Afliberceptvs |
9 |
5,25 |
6,9 |
13,5 |
PD (50.4) |
AE (26.9) |
PR (13.7) |
| |
|
|
|
Folfiri/Placebo |
8 |
4,52 |
4,7 |
12,0 |
PD (72.2) |
AE (12.2) |
PR (7.4) |
| Hoff |
2013 |
1076 |
1° |
Folfox/Xelox/Ced 20 mg |
9/10/6 |
NR |
8,6 |
19,7 |
PD (56.7) |
AE (22.5) |
PR (10.1) |
| |
|
|
|
Folfox/Xelox/Placebo |
11/11/7 |
NR |
8,3 |
18,9 |
PD (69.8) |
AE (13.9) |
PR (7.8) |
| Carrato |
2013 |
768 |
1° |
Folfiri/Sunitinib |
NR |
NR |
7,8 |
20,3 |
PD (42.4) |
AE (24.0) |
PR (4.6) |
| |
|
|
|
Folfiri/Placebo |
NR |
NR |
8,4 |
19,8 |
PD (39.0) |
AE (11.2) |
PR (5.8) |
| Loupakis |
2014 |
508 |
1° |
Folfiri/Bev |
12 |
NR |
9,7 |
31,0 |
PD (30.3) |
“Other
reasons” (3.9) |
AE (3.5) |
| |
|
|
|
Folofoxiri/Bev |
11 |
NR |
12,1 |
25,8 |
PD (13.6) |
AE (8.4) |
Deaths
(0.2%: 6 pts) |
| |
|
|
|
|
|
|
|
|
|
|
|
| Heinemann |
2014 |
752 |
1° |
Folfiri/Cet |
10 |
4,8 |
10,0 |
28,7 |
AE (15.0) |
“Other reasons” (9.4) |
| |
|
|
|
Folfiri/Bev |
12 |
5,3 |
10,3 |
25,0 |
AE (11.0) |
“Other reasons” (6.7) |
|
